ESMO 2023 | PSA limitations in prostate cancer: advancing treatment de-escalation with imaging biomarkers

Bertrand Tombal, MD, PhD, Université catholique de Louvain in Ottignies-Louvain-la-Neuve, Belgium, discusses the challenge of relying solely on PSA as a biomarker in treatment de-escalation strategies for rising PSA in prostate cancer. Prof. Tombal emphasizes the need for additional biomarkers, particularly advanced imaging such as PET PSMA or whole-body MRI, to better categorize patients’ responses. He highlights the importance of incorporating imaging biomarkers into trials to refine patient selection based on treatment response. This interview was conducted at the PROSCA/BLADDR 2023 conference in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.